尼尔马特雷尔维尔 - 里托纳维尔和维拉帕米尔引发的完全心脏阻塞
Evan Offord1, Michelle Nabi1, Michael Mankbadi1
1Division of Cardiovascular Medicine, Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.
里托纳维尔增强的尼马特里尔维尔 (帕克斯洛维德) 可以引起严重的药物相互作用. 将其与维拉帕米尔结合,导致急性损伤患者的完全心脏阻塞和休克.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 里托纳维尔增强的尼马特里尔维尔 (Paxlovid) 是一种关键的COVID-19治疗方法.
- 里托纳维尔是一种强大的细胞染色体P450 (CYP) 3A4抑制剂,增加了药物相互作用的风险.
- 维拉帕米尔是一种通道阻塞剂,通常用于心血管疾病.
研究的目的:
- 报告尼尔马特雷尔维尔 - 里托纳维尔和维拉帕米尔之间罕见而严重的药物相互作用.
- 为了突出这种相互作用导致的完全心脏阻塞和休克的潜力.
- 强调在临床实践中理解药理动力学关系的重要性.
主要方法:
- 病例报告详细介绍了一名患者经过尼尔马特里尔维尔 - 里托纳维尔和维拉帕米尔联合处方后出现不良事件.
- 对临床表现,管理和患者结果的审查.
- 在文献中搜索类似的记录案例.
主要成果:
- 患者出现了完全的心脏阻塞和休克,并因急性损伤而复杂化.
- 为了控制维拉帕米尔毒性的相互作用,使用液体复苏,上腺素和疗法来控制相互作用.
- 患者康复了,并以正常的鼻节律出院.
结论:
- 尼尔马特雷尔维尔 - 里托纳维尔和维拉帕米尔的组合可以导致危及生命的心血管事件.
- 这种药物相互作用很少发生,但很严重,需要仔细考虑.
- 临床医生必须在识别和管理这种相互作用时保持警,以防止不良结果.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
